Lai Wang
Chief Tech/Sci/R&D Officer bei BEIGENE, LTD.
Vermögen: 20 Mio $ am 31.03.2024
Profil
Herr Lai Wang ist Global Head-Research & Development bei BeiGene Ltd.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BEIGENE LTD
0,13% | 26.06.2023 | 1 658 215 ( 0,13% ) | 20 Mio $ | 31.03.2024 |
Aktive Positionen von Lai Wang
| Unternehmen | Position | Beginn |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 01.04.2021 |
Ehemalige bekannte Positionen von Lai Wang
| Unternehmen | Position | Ende |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Ausbildung von Lai Wang
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
